SG10202007233TA - IMMUNOGLOBULINS BINDING HUMAN Vγ9Vδ2 T CELL RECEPTORS - Google Patents

IMMUNOGLOBULINS BINDING HUMAN Vγ9Vδ2 T CELL RECEPTORS

Info

Publication number
SG10202007233TA
SG10202007233TA SG10202007233TA SG10202007233TA SG10202007233TA SG 10202007233T A SG10202007233T A SG 10202007233TA SG 10202007233T A SG10202007233T A SG 10202007233TA SG 10202007233T A SG10202007233T A SG 10202007233TA SG 10202007233T A SG10202007233T A SG 10202007233TA
Authority
SG
Singapore
Prior art keywords
cell receptors
binding human
human vγ9vδ2
immunoglobulins binding
immunoglobulins
Prior art date
Application number
SG10202007233TA
Inventor
Der Vliet Johannes Jelle Van
Bruin Renée Cornelia Gerarda De
Gruijl Tanja Denise De
Hendrik Marinus Willem Verheul
Original Assignee
Lava Therapeutics B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lava Therapeutics B V filed Critical Lava Therapeutics B V
Publication of SG10202007233TA publication Critical patent/SG10202007233TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
SG10202007233TA 2014-04-10 2015-04-10 IMMUNOGLOBULINS BINDING HUMAN Vγ9Vδ2 T CELL RECEPTORS SG10202007233TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL2012604 2014-04-10

Publications (1)

Publication Number Publication Date
SG10202007233TA true SG10202007233TA (en) 2020-09-29

Family

ID=50896416

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202007233TA SG10202007233TA (en) 2014-04-10 2015-04-10 IMMUNOGLOBULINS BINDING HUMAN Vγ9Vδ2 T CELL RECEPTORS
SG11201609417VA SG11201609417VA (en) 2014-04-10 2015-04-10 IMMUNOGLOBULINS BINDING HUMAN Vγ9Vδ2 T CELL RECEPTORS

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201609417VA SG11201609417VA (en) 2014-04-10 2015-04-10 IMMUNOGLOBULINS BINDING HUMAN Vγ9Vδ2 T CELL RECEPTORS

Country Status (11)

Country Link
US (4) US10501540B2 (en)
EP (1) EP3129404A1 (en)
JP (4) JP6617138B2 (en)
KR (2) KR102359264B1 (en)
CN (2) CN106536557B (en)
AU (3) AU2015244489B2 (en)
CA (1) CA2948812A1 (en)
EA (2) EA039086B1 (en)
MX (2) MX2016013332A (en)
SG (2) SG10202007233TA (en)
WO (1) WO2015156673A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10356636B2 (en) * 2017-04-03 2019-07-16 Qualcomm Incorporated Techniques and apparatuses to improve drone-mounted user equipment performance
CN108659130B (en) * 2018-05-28 2021-09-10 长春力太生物技术有限公司 Anti-carcinoembryonic antigen nano antibody and application thereof
CN112703201A (en) * 2018-07-05 2021-04-23 诺沃班德畜牧业治疗公司 Antibodies against poultry pathogens and uses thereof
MX2021003234A (en) 2018-09-19 2021-07-16 Lava Therapeutics N V Dual acting cd1d immunoglobulin.
EP3890773A4 (en) * 2018-11-08 2022-11-09 Orionis Biosciences, Inc. Modulation of dendritic cell lineages
US11098093B2 (en) 2019-01-07 2021-08-24 Shattuck Labs, Inc. Heterodimeric proteins for modulating gamma delta T cells
KR20210113244A (en) 2019-01-07 2021-09-15 샤턱 랩스 인코포레이티드 Heterodimeric Proteins to Regulate Gamma Delta T Cells
CA3128148A1 (en) 2019-02-01 2020-08-06 Lava Therapeutics B.V. Novel cd40-binding antibodies
NL2022494B1 (en) 2019-02-01 2020-08-19 Lava Therapeutics B V Novel CD40-binding antibodies
JP7308477B2 (en) * 2019-03-11 2023-07-14 パナソニックＩｐマネジメント株式会社 Antibody, complex, detection device and detection method using the same
AU2020267504A1 (en) * 2019-05-08 2021-12-02 Janssen Biotech, Inc. Materials and methods for modulating T cell mediated immunity
EP3792283A1 (en) 2019-09-16 2021-03-17 Lava Therapeutics B.V. Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies
KR20230042035A (en) 2020-07-08 2023-03-27 라바 테라퓨틱스 엔.브이. Antibodies capable of binding PSMA and the gamma-delta T cell receptor
WO2022093888A1 (en) * 2020-10-28 2022-05-05 Janssen Biotech, Inc. Compositions and methods for modulating delta gamma chain mediated immunity
US20220168407A1 (en) 2020-11-05 2022-06-02 Dcprime B.V. Use of tumor-independent antigens in immunotherapies
WO2022116952A1 (en) * 2020-12-01 2022-06-09 苏州克睿基因生物科技有限公司 Antigen-binding protein targeting cd70 and use thereof
EP4259660A1 (en) 2020-12-10 2023-10-18 LAVA Therapeutics N.V. Antibodies that bind gamma-delta t cell receptors
AU2022225091A1 (en) 2021-02-26 2023-09-07 LAVA Therapeutics N.V. Antibodies that bind CD123 and gamma-delta T cell receptors
WO2023037333A1 (en) 2021-09-13 2023-03-16 Janssen Biotech, Inc CD33 X Vδ2 MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER
WO2023067138A1 (en) 2021-10-21 2023-04-27 LAVA Therapeutics N.V. Uses of gamma delta t cell activating antibodies
TW202334233A (en) * 2022-01-05 2023-09-01 美商英伊布里克斯公司 Gamma delta t-cell-binding polypeptides and uses thereof
CN115043933B (en) * 2022-03-31 2023-08-08 深圳市人民医院 Nanometer antibody targeting novel coronavirus and preparation method and application thereof
EP4285926A1 (en) 2022-05-30 2023-12-06 LAVA Therapeutics N.V. Combination treatment for chronic lymphocytic leukemia
EP4292610A1 (en) 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Variant antibodies that bind gamma-delta t cell receptors
EP4292609A1 (en) 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Compositions comprising antibodies that bind gamma-delta t cell receptors
CN116178538A (en) * 2023-01-05 2023-05-30 暨南大学 Nanometer antibody targeting heat shock protein 70 and preparation method and application thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2698880B1 (en) * 1992-11-25 1995-02-24 Inst Nat Sante Rech Med Process for the production of soluble T receptors, products thus obtained and their use in diagnostic or therapeutic compositions.
KR20050092029A (en) * 2003-01-10 2005-09-16 아블린쓰 엔.브이. Recombinant vhh single domain antibody from camelidae against von willebrand factor (vwf) or against collagen
EP1627231A2 (en) * 2003-05-23 2006-02-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Improvements to gamma delta t cell-mediated therapy
DK1753783T3 (en) * 2004-06-03 2014-11-17 Novlmmune Sa Anti-CD3 antibodies, and methods of use thereof
ITRM20070437A1 (en) * 2007-08-10 2009-02-11 Istituto Naz Per Le Malattie I METHOD FOR THE GENERATION AND EXPANSION OF CELLS T RANGE / DELTA REGULATORY CELLS SOON OBTAINED AND THEIR APPLICATIONS
US8012466B2 (en) * 2008-01-31 2011-09-06 University Of Iowa Research Foundation Immunogenic compositions for activating γδ T cells
CN102154205A (en) * 2011-01-31 2011-08-17 郑骏年 Method for preparing high-purity and high-cytotoxin-activity gamma delta T cells
AU2013201422B2 (en) * 2012-01-23 2015-04-09 Ablynx Nv Sequences directed against hepatocyte growth factor (HFG) and polypeptides comprising the same for the treatment of cancers and/or tumors
CN103571791B (en) * 2012-02-10 2015-05-13 深圳市合一康生物科技股份有限公司 Morphology and purity and immunophenotyping detection method of human (gamma)(delta)T cells
JP6403663B2 (en) * 2012-03-28 2018-10-10 ガデタ・ベー・フェー Combinatorial gamma 9 delta 2 T cell receptor chain exchange

Also Published As

Publication number Publication date
KR20170019343A (en) 2017-02-21
CN106536557A (en) 2017-03-22
MX2021009674A (en) 2021-09-08
JP7342202B2 (en) 2023-09-11
US20170029506A1 (en) 2017-02-02
EA201692039A1 (en) 2017-05-31
JP2017513521A (en) 2017-06-01
JP7094931B2 (en) 2022-07-04
US20220098301A1 (en) 2022-03-31
US20230212290A1 (en) 2023-07-06
JP2023165723A (en) 2023-11-17
AU2023204215A1 (en) 2023-07-20
KR102601469B1 (en) 2023-11-14
JP2022136078A (en) 2022-09-15
EA039086B1 (en) 2021-12-01
JP6617138B2 (en) 2019-12-11
EP3129404A1 (en) 2017-02-15
KR102359264B1 (en) 2022-02-04
US10501540B2 (en) 2019-12-10
US20190263908A1 (en) 2019-08-29
SG11201609417VA (en) 2016-12-29
US11384145B2 (en) 2022-07-12
WO2015156673A1 (en) 2015-10-15
MX2016013332A (en) 2017-05-01
AU2015244489B2 (en) 2020-08-27
AU2020213325B2 (en) 2023-03-30
CN113105550A (en) 2021-07-13
KR20220021015A (en) 2022-02-21
AU2015244489A1 (en) 2016-12-01
CA2948812A1 (en) 2015-10-15
CN106536557B (en) 2021-05-04
AU2020213325A1 (en) 2020-08-27
EA202192165A1 (en) 2021-12-31
JP2020029461A (en) 2020-02-27

Similar Documents

Publication Publication Date Title
SG11201609417VA (en) IMMUNOGLOBULINS BINDING HUMAN Vγ9Vδ2 T CELL RECEPTORS
IL262144A (en) T cell receptors
ZA201806866B (en) T cell receptors
ZA201806862B (en) T cell receptors
ZA201806865B (en) T cell receptors
HUE062008T2 (en) T cell receptors
IL264425B1 (en) Anti-kras-g12d t cell receptors
IL251524B (en) T cell receptors
GB201522592D0 (en) T cell receptors
PT3101132T (en) Anti-transthyretin human antibody
PL3180356T3 (en) Human anti-fgfr4 antibody
LT3433270T (en) T cell receptors
PL2998145T3 (en) Canvas cover
GB201518991D0 (en) T cell receptors
GB201403306D0 (en) Binding Polypeptides